Harvard University’s Latest Portfolio: 5 Best Biotech Stock Picks

1. AbCellera Biologics Inc. (NASDAQ:ABCL)

Harvard Management’s Stake Value: $43,719,000

Percentage of Harvard Management’s 13F Portfolio: 5.06%

Number of Hedge Fund Holders: 17

AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotechnology company that develops human antibodies by leveraging technological advancements in artificial intelligence and machine learning. On August 9, AbCellera Biologics Inc. (NASDAQ:ABCL) announced earnings for the second quarter of fiscal 2022. The company grew its revenue by 66% year over year and generated a revenue of $45.9 million for the quarter.

As of September 14, AbCellera Biologics Inc. (NASDAQ:ABCL) has gained 39.5% over the past six months.

On August 10, Credit Suisse analyst Tiago Fauth revised his price target on AbCellera Biologics Inc. (NASDAQ:ABCL) to $34 from $40 and reiterated a buy-side Outperform rating on the shares.

At the end of Q2 2022, 17 hedge funds were bullish on AbCellera Biologics Inc. (NASDAQ:ABCL) and held stakes worth roughly $320.5 million in the company. This is compared to 17 positions in the previous quarter with stakes worth $329 million.

As of June 30, Harvard Management Company owns more than 4 million shares of AbCellera Biologics Inc. (NASDAQ:ABCL). The fund’s stakes are valued at $43.7 million in the company.

You can also take a look at 10 Best Biotech Penny Stocks To Buy and 11 Best Pharma and Biotech Stocks to Buy.

Follow Insider Monkey on Twitter